LGALS3 and metabolic dysfunction-associated steatohepatitis: However, an inhibitor of Gal3 called Belapectin was used in patients with NASH and cirrhosis and showed no significant effect on histological scores of fibrosis or on hepatic vein pressure gradient in patients suffering from portal hypertension (Chalasani et al., 2020).